North Dakota State Investment Board Makes New $611,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

North Dakota State Investment Board acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 6,791 shares of the medical equipment provider’s stock, valued at approximately $611,000.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Zimmer Biomet by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after buying an additional 192,517 shares in the last quarter. Dodge & Cox increased its stake in Zimmer Biomet by 5.1% during the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after buying an additional 1,118,710 shares in the last quarter. Capital International Investors increased its stake in Zimmer Biomet by 11.5% during the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after buying an additional 778,467 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Zimmer Biomet by 1.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,789,200 shares of the medical equipment provider’s stock worth $373,239,000 after buying an additional 58,335 shares in the last quarter. Finally, M&T Bank Corp increased its stake in Zimmer Biomet by 15,705.6% during the 4th quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock worth $321,158,000 after buying an additional 3,548,998 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.28% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on ZBH shares. Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. UBS Group restated a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Stifel Nicolaus dropped their price target on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. dropped their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $102.80.

Zimmer Biomet Price Performance

ZBH stock opened at $85.39 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The business has a 50 day simple moving average of $88.99 and a 200-day simple moving average of $91.02. The firm has a market capitalization of $16.52 billion, a PE ratio of 22.18, a price-to-earnings-growth ratio of 1.98 and a beta of 0.48. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business’s revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were issued a $0.24 dividend. The ex-dividend date was Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.